Clinical and
endoscopic remission

Review data

Banner Image

1-week symptomatic
response data

Explore results

Banner Image

2-year open-label
LTE data

View the latest

Banner Image

View the established safety profile across pivotal trials

Tremfya withme Image
Tremfya withme Image
Tremfya withme Image

Once a decision has been
made to prescribe TREMFYA®

TREMFYA withMe provides support to help your patients start and stay on TREMFYA®

teal vector
teal vector
global

Schedule a meeting with a local representative of Johnson & Johnson

References: 1. TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Atreya R, Abreu MT, Krueger JG, et al. Guselkumab, an
IL-23p19 subunit–specific monoclonal antibody,
binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells. Poster presented at: 18th Congress of the European Crohn’s and Colitis Organisation (ECCO); March
1-4, 2023; Copenhagen, Denmark. Poster P504. 3. Sewell GW, Kaser A. Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention. J Crohns Colitis. 2022;16(suppl 2):ii3-ii19. doi: 10.1093/ecco-jcc/jjac034 4. Krueger JG, Eyerich K, Kuchroo VK, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217. doi: 10.3389/
fimmu.2024.1331217